Depressive Disorder, Major Clinical Trials

16 studies are recruiting for depressive disorder, major in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

   Background: Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective. Researchers want to know if a faster-acting drug, (2R,6R)-hydroxynorketamine (HNK), can…

   Stage

   Phase 2

   Ages

   18 to 70

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Mental Health (NIMH)

   See if you can join NCT06511908 on ClinicalTrials.gov

2. MOCHA: Embedded Inpatient Mental Health Care for High-Risk Perinatal Patients

   Pregnant and postpartum patients hospitalized for medical complications experience high rates of depression, anxiety, and trauma-related symptoms, yet access to timely psychiatric care during obstetric hospitalization is limited. Project MOCHA integrates early mental health screening, trauma-inform…

   Stage

   Not phased

   Ages

   18 to 100

   Site

   Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana

   Run by

   Indiana University

   See if you can join NCT07540585 on ClinicalTrials.gov

3. Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

   The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia sympto…

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   University of Arizona, Tucson, Arizona

   Locations

   205 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06559306 on ClinicalTrials.gov

4. A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

   The purpose of this study is to evaluate how well JNJ-54135419 works (efficacy) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (MDD, a mental disorder characterized by a persistent feeling of sadness and loss of interest in activiti…

   Stage

   Phase 3

   Ages

   12 to 17

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   39 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07227454 on ClinicalTrials.gov

5. A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

   The main purpose of this study is to assess how well the study drug (JNJ-42847922) works (efficacy) compared with placebo in improving depressive symptoms in participants with major depressive disorder ([MDD], a common mood disorder that causes a lasting feeling of sadness and a loss of interest in…

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   SanRo Clinical Research Group LLC WCG Clinical Network, Bryant, Arkansas

   Locations

   39 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07573176 on ClinicalTrials.gov

6. Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS

   This study evaluates the antidepressant effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), in individuals with borderline personality disorder (BPD) or trait and comorbid mood depressive disorder (MDD) or bipolar II disord…

   Stage

   Not phased

   Ages

   18 to 80

   Site

   Stanford Hospital, Stanford, California

   Run by

   Stanford University

   See if you can join NCT04870255 on ClinicalTrials.gov

7. A Study of Brenipatide in Adult Participants With Major Depressive Disorder

   This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into three periods as follows: a screening period that will last approximately 1 month, a …

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   Accellacare - Moorpark, Moorpark, California

   Locations

   179 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07412756 on ClinicalTrials.gov

8. Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation

   The study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach/avoidance decision-making in unmedicated individuals with major depressive disorder (MDD) and anxiety disorders. More specifically, the study aims to investigate dysregulat…

   Stage

   Phase 2

   Ages

   18 to 45

   Site

   Mclean Hospital, Belmont, Massachusetts

   Run by

   Mclean Hospital

   See if you can join NCT05232032 on ClinicalTrials.gov

9. Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

   The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid recept…

   Stage

   Phase 1

   Ages

   18 to 60

   Site

   Yale University, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT05915013 on ClinicalTrials.gov

10. Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia

    The purpose of this research is to learn more about a new treatment for individuals with Major Depressive Disorder (MDD) with heightened symptoms of anhedonia (i.e. loss of pleasure or interest in activities). The treatment is called Prism, and it is a software device intended for a novel form of n…

    Stage

    Not phased

    Ages

    22 to 75

    Site

    Butler Hospital, Providence, Rhode Island

    Locations

    3 in total

    Run by

    GrayMatters Health Ltd.

    See if you can join NCT06982820 on ClinicalTrials.gov

11. NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits

    Most clinical major depression responds to standard treatments (medication and psychotherapy); however, a significant subset of depressed patients (15-20%) do not respond to these treatments and are referred to as treatment-resistant major depression (TRMD). New treatments for TRMD are needed, and …

    Stage

    Phase 1

    Ages

    18 to 65

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT02994433 on ClinicalTrials.gov

12. Biomarkers of Depression and Treatment Response

    This study is a stratified, parallel-group, single-center study utilizing multimodal imaging techniques to identify biomarkers for Major Depressive Disorder (MDD). The study goal is to identify biomarkers for MDD and treatment response that can be implemented in clinical diagnosis and care as valid…

    Stage

    Not phased

    Ages

    18 to 70

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT04581902 on ClinicalTrials.gov

13. Dosing rTMS for Depression Post-SCI

    Depression is a leading cause of disability worldwide and is more commonly seen in individual's post-spinal cord injury (SCI) than in the general population. Depression post-SCI impacts an individuals' quality of life and recovery. It has been reported that among Veterans with an SCI, those without…

    Stage

    Not phased

    Ages

    18 to 60

    Site

    Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina

    Run by

    VA Office of Research and Development

    See if you can join NCT05553353 on ClinicalTrials.gov

14. Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness

    Many individuals with serious mental illness have difficulty accurately interpreting interpersonal cues and effectively engaging in social exchanges. Difficulties related to the interpersonal aspects of work can lead to isolation, poor productivity, and job loss. The goals of this study are to: 1) …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota

    Run by

    VA Office of Research and Development

    See if you can join NCT05491538 on ClinicalTrials.gov

15. Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

    This study is a mechanistic randomized controlled trial that investigates whether inhibition of tumor necrosis factor signaling via intravenous infusion of infliximab improves psychomotor speed and executive functioning in depressed individuals who exhibit an inflammatory phenotype.

    Stage

    Phase 2

    Ages

    25 to 50

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT06136546 on ClinicalTrials.gov

16. InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI

    The purpose of this randomized controlled trial is to evaluate whether the InMotion intervention, delivered via telehealth (using a HIPAA-compliant video platform or phone), which uses evidence-based behavioral and motivational counseling to increase daily physical activity, is an effective treatme…

    Stage

    Not phased

    Ages

    18 to 64

    Site

    University of Washington Medical Center, Seattle, Washington

    Run by

    University of Washington

    See if you can join NCT06005194 on ClinicalTrials.gov